X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ReNu (cryopreserved amniotic suspension allograft) has shown promising anti-inflammatory and chondroregenerative potential. It is being studied for the treatment of moderate to severe symptomatic knee osteoarthritis (OA).
Lead Product(s): Cryopreserved Amniotic Suspension Allograft
Therapeutic Area: Musculoskeletal Product Name: ReNu
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Details:
The Phase 3 study is a prospective, double-blind, multicenter, placebo-controlled, parallel group, randomized control trial (RCT) of ReNu in 474 subjects with moderate to severe symptomatic knee osteoarthritis.
Lead Product(s): Amniotic suspension allograft
Therapeutic Area: Musculoskeletal Product Name: ReNu
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 14, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
